Skip to main content

Share story

Robotics AI

Berkeley tests AI-written robot programs with success rates up to 99%

Berkeley tests AI-written robot programs with success rates up to 99% Image: Primary
UC Berkeley researchers tested an approach that uses AI coding agents to write and refine robot programs, reaching success rates up to 99% in tasks where baseline imitation learning achieved 20%, IEEE Spectrum reported. Berkeley and Nvidia are announcing the approach at the Conference on Robot Learning. Agents divide tasks into parts, generate code using existing robotics tools and test it in simulation. They can also adjust simulations using video of real-world failures. The resulting code is readable by engineers. The results match human hand-engineered performance in the reported tests, but translating simulated behavior into reliable physical contact remains an unresolved challenge, according to Intrinsic chief science officer Torsten Kroeger.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from IEEE Spectrum and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.